Targovax has decided to expand the on-going phase I/II clinical study CT-TG01-01 with a new group of up to 13 patients.
TG01, a novel peptide vaccine against cancer specific RAS mutations, is tested in combination with gemcitabine as adjuvant treatment in resected pancreatic cancer. The purpose of the expansion is to build on the positive findings of immune responses to further optimise the TG01 treatment regimen and safety profile of the combination therapy. The submission for regulatory approvals is planned for end of March. “Although we have already achieved the primary endpoints of the study we believe that there is a potential for further optimisation of the combination treatment regimen.